m_and_a
confidence high
sentiment neutral
materiality 0.85
Salarius completes acquisition of Decoy Therapeutics, raises ~$6.3M in public offering
Decoy Therapeutics Inc.
- Closed merger with Decoy Therapeutics on Nov 12; issued Series A/B Preferred Stock convertible at 2,800:1 ratio post-anti-dilution adjustment.
- Public offering priced at $1.50/unit (common + Series A/B warrants); net proceeds ~$6.3M, closed Nov 12.
- Frederick Pierce (Decoy CEO) appointed CEO, replacing Mark Rosenblum who remains CFO; Dr. Barbara Hibner as CSO, Peter Marschel as CBO.
- Board change: Pierce appointed Class II director; Bruce McCreedy resigned, not due to any disagreement.
- Warrants: Series A (5-yr term, $1.50 exercise), Series B (1-yr term, $1.50), Pre-funded ($0.0001). Representative warrants also issued.